Companion Diagnostics Market Is Predicted To Reach $22.69 Billion, Expanding At 21.1% CAGR Through 2030
What Are The Anticipated Developments In The Companion Diagnostics Market’s Size And Overall Value Through 2030?
The companion diagnostics market size has grown exponentially in recent years. It will grow from $8.69 billion in 2025 to $10.54 billion in 2026 at a compound annual growth rate (CAGR) of 21.3%. The growth in the historic period can be attributed to growth in targeted cancer therapies, expansion of oncology clinical trials, increased collaboration between pharma and diagnostics firms, rising cancer incidence rates, regulatory approvals for companion tests.
The companion diagnostics market size is expected to see exponential growth in the next few years. It will grow to $22.7 billion in 2030 at a compound annual growth rate (CAGR) of 21.1%. The growth in the forecast period can be attributed to increasing demand for personalized treatment selection, rising investments in precision medicine, expansion of immuno-oncology pipelines, growing adoption of ai-driven diagnostic interpretation, increasing regulatory emphasis on diagnostic-drug co-development. Major trends in the forecast period include increasing adoption of precision oncology diagnostics, rising integration of companion diagnostics in drug development, growing use of ngs-based diagnostic platforms, expansion of biomarker-driven therapies, enhanced focus on personalized medicine.
Claim Your Free Report Sample Today:
Which Primary Market Drivers Are Fueling Momentum In The Companion Diagnostics Market?
The increasing number of targeted therapies is expected to propel the growth of the companion diagnostics market. Targeted therapy is a pharmacological therapy that targets particular characteristics of cancer cells to inhibit the growth and spread of the disease. The medications circulate throughout the body but have a more targeted effect than chemotherapy and frequently have fewer adverse effects. Biological marker-based companion diagnostic testing for targeted cancer therapy is becoming an essential part of personalized cancer care. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based hospital and health care organization, in 2023, the FDA approved 16 new personalized treatments for rare disease patients, up from 6 in 2022. Therefore, the surge in targeted therapies drives growth in the companion diagnostics market.
What Major Market Segments Contribute To Shaping The Overall Framework Of The Companion Diagnostics Market?
The companion diagnostics market covered in this report is segmented –
1) By Product And Service: Assays, Kits And Reagents, Software And Services
2) By Technology: Polymerase Chain Reaction, Next-Generation Sequencing, In Situ Hybridization, Immunohistochemistry
3) By Indication: Lung Cancer, Breast Cancer, Colorectal Cancer, Leukemia, Melanoma
4) By End-User: Pharmaceutical And Biopharmaceutical Companies, Reference Laboratories, Contract Research Organizations
Subsegments:
1) By Assays: Polymerase Chain Reaction (PCR) Assays, Immunohistochemistry (IHC) Assays, Next-Generation Sequencing (NGS) Assays, In Situ Hybridization (ISH) Assays
2) By Kits And Reagents: Diagnostic Kits, Detection Reagents, Control Reagents
3) By Software And Services: Data Analysis Software, Interpretation Software, Custom Development Services, Consulting and Support Services
Which Trends Are Expected To Steer The Evolution Of The Companion Diagnostics Market?
Major companies operating in the companion diagnostics market are collaborating to develop innovative treatment solutions to enhance personalized medicine, improve patient outcomes, and optimize the effectiveness of targeted therapies. Collaboration of the companies will accelerate the development and commercialization of companion diagnostics (CDx) for hematology and oncology treatments. For instance, in January 2024, Agilent Technologies, Inc., a US-based company that provides instruments, software, services, and consumables for laboratories, announced an agreement with Incyte, a US-based pharmaceutical company. This will bring together Agilent’s expertise and proven track record in the development of companion diagnostics (CDx) to support the development and commercialization of Incyte’s hematology and oncology portfolio. This collaboration allows Agilent to expand its CDx portfolio with new biomarkers, while Incyte benefits from Agilent's expertise in assay development, regulatory approvals, and commercialization to support clinical trials and CDx registration in the U.S. and Europe.
Who Are The Established And Emerging Players Expanding Their Footprint In The Companion Diagnostics Market?
Major companies operating in the companion diagnostics market are F Hoffmann-La Roche Ltd., Agilent Technologies Inc., Qiagen NV, Thermo Fisher Scientific Inc., Abbott Laboratories Inc., Amoy Diagnostics Co. Ltd., Danaher Corporation, Guardant Health Inc., Illumina Inc., Myriad Genetics Inc., Siemens Healthcare GmbH, Almac Group, Caris Life Sciences, Cepheid Inc., Diaceutics plc, Epic Sciences Inc., Foundation Medicine Inc., Genomic Health Inc., Grail Inc., Hologic Inc., HTG Molecular Diagnostics Inc., Inivata Ltd., Invivoscribe Inc., MolecularMD Corporation, Natera Inc., NeoGenomics Laboratories Inc., Personal Genome Diagnostics Inc., Precision Therapeutics Inc., Prometheus Laboratories Inc., Sysmex Corporation, Ventana Medical Systems
Get Your In-Depth Companion Diagnostics Market Report Now:
Which Regions Demonstrate The Highest Growth Momentum In The Companion Diagnostics Market?
North America was the largest region in the companion diagnostics market in 2025. The regions covered in the companion diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Contact Us:
The Business Research Company: https://thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Comments
Post a Comment